Table A1.

Summary of CAF Changes During Treatment and Associations Between CAF Changes and Outcome

Change	CAF
CAFs that increased during treatment
V	VEGF, IL-8, G-CSF, IL-17
CP	MCP-1
VCP	MCP-1, eotaxin
CAFs that decreased during treatment
V	sVEFGR-2
CP	IL-12, IL-1RA, MMP-9, IL-4, IL-10, IL-13, sVEGFR-2, MIP-1α, IP-10
VCP	IL-12, IL-1RA, MMP-9
CAF increases associated with improved PFS outcome
V	ICAM-1, osteopontin, sIL-2R, IL-5
CP	IL-13, IL-15, IL-17
VCP	IL-12, IP-10, MIP-1α
CAF increases associated with inferior PFS outcome
V	VEGF
CP	MMP-9, IL-15
VCP	IL-8, IFN-α
CAF changes predictive of PFS benefit from treatment
V	ICAM-1 (increase → superior PFS); VEGF (increase → inferior PFS)
CP	IL-17 (increase → superior PFS)
VCP	sIL-2R (increase → superior PFS); IL-8 (increase → inferior PFS); IFN-α (increase → inferior PFS)

Abbreviations: CAF, cytokine and angiogenic factor; V, vandetanib; VEGF, vascular endothelial growth factor; IL, interleukin; G-CSF, granulocyte colony-stimulating factor; CP, carboplatin and paclitaxel; MCP-1, macrophage chemoattractant protein-1; VCP, vandetanib, carboplatin, and paclitaxel; sVEGFR-2, soluble vascular endothelial growth factor receptor 2; IL-1RA, interleukin-1 receptor antagonist; MMP-9, matrix metalloproteinase 9; MIP-1α, macrophage inflammatory protein 1α; IP-10, interferon gamma–induced protein 10; PFS, progression-free survival; ICAM-1, intercellular adhesion molecule 1; sIL-2R, soluble interleukin-2 receptor; IFN-α, interferon alfa.